122 related articles for article (PubMed ID: 7663590)
1. Research review: use of activated clotting time to monitor heparin therapy in coronary patients.
Noureddine SN
Am J Crit Care; 1995 Jul; 4(4):272-7; quiz 278-9. PubMed ID: 7663590
[TBL] [Abstract][Full Text] [Related]
2. Clinical safety and cost of heparin titration using bedside activated clotting time.
Thomason T; Riegel B; Jessen D; Smith SC; Gocka I; Rich M
Am J Crit Care; 1993 Jan; 2(1):81-7. PubMed ID: 8353584
[TBL] [Abstract][Full Text] [Related]
3. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
Nath FC; Muller DW; Rosenschein U; Ellis SG; Topol EJ
Can J Cardiol; 1993 Nov; 9(9):797-801. PubMed ID: 8281479
[TBL] [Abstract][Full Text] [Related]
4. Heparin monitoring in the coronary care unit after percutaneous transluminal coronary angioplasty.
Varah N; Smith J; Baugh RF
Heart Lung; 1990 May; 19(3):265-70. PubMed ID: 2341265
[TBL] [Abstract][Full Text] [Related]
5. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty.
Pitney MR; Kelly SA; Allan RM; Giles RW; McCredie M; Walsh WF
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):145-50. PubMed ID: 8808069
[TBL] [Abstract][Full Text] [Related]
6. The truth about activated clotting time measurements.
Bittl JA
Catheter Cardiovasc Interv; 2005 Jul; 65(3):338-9. PubMed ID: 15864807
[No Abstract] [Full Text] [Related]
7. Clotting, activated partial thromboplastin and coagulation times in monitoring heparin therapy.
Kurec AS; Morris MW; Davey FR
Ann Clin Lab Sci; 1979; 9(6):494-500. PubMed ID: 518012
[TBL] [Abstract][Full Text] [Related]
8. [-Value of activated blood coagulation time in monitoring anticoagulation during coronary angioplasty-].
Kunert M; Sorgenicht R; Scheuble L; Ketteler T; Lürken E; Meyer I; Müller A; Emmerich K; Gülker H
Z Kardiol; 1996 Feb; 85(2):118-24. PubMed ID: 8650981
[TBL] [Abstract][Full Text] [Related]
9. Whole blood coagulation analyzers.
Health Devices; 1997 Aug; 26(8):296-332. PubMed ID: 9283920
[TBL] [Abstract][Full Text] [Related]
10. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation.
Maul TM; Wolff EL; Kuch BA; Rosendorff A; Morell VO; Wearden PD
Pediatr Crit Care Med; 2012 Nov; 13(6):e363-71. PubMed ID: 22940857
[TBL] [Abstract][Full Text] [Related]
11. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
12. Percutaneous transluminal coronary angioplasty: comparison of arterial vs. venous activated clotting time.
Pesola GR; Johnson A; Pesola DA
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):140-4. PubMed ID: 8808068
[TBL] [Abstract][Full Text] [Related]
13. [The use of activated clotting time (ACT) to optimize heparinization during coronary angioplasty. The nursing personnel of the Hemodynamics Laboratory].
Dellavalle A; Steffenino G; Ribichini F; Russo P; Conte L; Conte E; Uslenghi E
G Ital Cardiol; 1995 Apr; 25(4):445-51. PubMed ID: 7642051
[TBL] [Abstract][Full Text] [Related]
14. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
[TBL] [Abstract][Full Text] [Related]
15. Optimal activated clotting time during percutaneous coronary intervention.
Hanratty CG; Ward M
Circulation; 2001 Oct; 104(15):E83-4. PubMed ID: 11591634
[No Abstract] [Full Text] [Related]
16. Venous activated clotting time after intra-arterial heparin: effect of site of administration and timing of sampling.
Kerensky RA; Azar GJ; Bertolet B; Hill JA; Kutcher MA
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):151-3. PubMed ID: 8808070
[TBL] [Abstract][Full Text] [Related]
17. When we "act" on ACT levels: activated clotting time measurements to guide heparin administration during and after interventional procedures.
Klein LW; Agarwal JB
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):154-7. PubMed ID: 8808071
[TBL] [Abstract][Full Text] [Related]
18. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
[TBL] [Abstract][Full Text] [Related]
19. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of drawing coagulation samples from heparinized arterial lines.
Templin K; Shively M; Riley J
Am J Crit Care; 1993 Jan; 2(1):88-95. PubMed ID: 8353585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
